BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 10999782)

  • 1. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.
    Mauras N; Martinez V; Rini A; Guevara-Aguirre J
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3036-42. PubMed ID: 10999782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.
    Hayes VY; Urban RJ; Jiang J; Marcell TJ; Helgeson K; Mauras N
    J Clin Endocrinol Metab; 2001 May; 86(5):2211-9. PubMed ID: 11344229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism.
    Mauras N; O'Brien KO; Welch S; Rini A; Helgeson K; Vieira NE; Yergey AL
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1686-94. PubMed ID: 10770216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects.
    Mauras N
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2633-7. PubMed ID: 7673406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rhIGF-I administration in humans: differential metabolic effects of bolus vs. continuous subcutaneous delivery.
    Mauras N; Martha PM; Quarmby V; Haymond MW
    Am J Physiol; 1997 Apr; 272(4 Pt 1):E628-33. PubMed ID: 9142884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity.
    Mauras N; Hayes V; Welch S; Rini A; Helgeson K; Dokler M; Veldhuis JD; Urban RJ
    J Clin Endocrinol Metab; 1998 Jun; 83(6):1886-92. PubMed ID: 9626114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect.
    Mauras N; Beaufrere B
    J Clin Endocrinol Metab; 1995 Mar; 80(3):869-74. PubMed ID: 7533772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N; Doi SQ; Shapiro JR
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone action in puberty: effects by gender.
    Mauras N; Bishop K; Welch S
    Growth Horm IGF Res; 2007 Dec; 17(6):463-71. PubMed ID: 17566776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin is suppressed during infusion of recombinant human insulin-like growth factor I (rhIGF I) in normal rats.
    Böni-Schnetzler M; Hauri C; Zapf J
    Diabetologia; 1999 Feb; 42(2):160-6. PubMed ID: 10064095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
    Guevara-Aguirre J; Vasconez O; Martinez V; Martinez AL; Rosenbloom AL; Diamond FB; Gargosky SE; Nonoshita L; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans.
    Mauras N; Horber FF; Haymond MW
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1192-7. PubMed ID: 1430078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women.
    Thompson JL; Butterfield GE; Marcus R; Hintz RL; Van Loan M; Ghiron L; Hoffman AR
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1845-52. PubMed ID: 7539817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy--a clinical research center study.
    Vlachopapadopoulou E; Zachwieja JJ; Gertner JM; Manzione D; Bier DM; Matthews DE; Slonim AE
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3715-23. PubMed ID: 8530624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.